Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,053 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L.
Uemura T, Kenmotsu H, Hazama D, Teraoka S, Kobe H, Azuma K, Yamaguchi T, Masuda T, Yokoyama T, Otsubo K, Haratani K, Hayakawa D, Oki M, Takemoto S, Ozaki T, Akashi Y, Hata A, Hashimoto H, Yamamoto N, Nakagawa K. Uemura T, et al. Among authors: ozaki t. Cancer Med. 2023 Dec;12(23):21097-21110. doi: 10.1002/cam4.6668. Epub 2023 Nov 10. Cancer Med. 2023. PMID: 37948122 Free PMC article.
Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L).
Kato R, Hayashi H, Chiba Y, Miyawaki E, Shimizu J, Ozaki T, Fujimoto D, Toyozawa R, Nakamura A, Kozuki T, Tanaka K, Teraoka S, Usui K, Nishino K, Hataji O, Ota K, Ebi N, Saeki S, Akazawa Y, Okuno M, Yamamoto N, Nakagawa K. Kato R, et al. Among authors: ozaki t. J Immunother Cancer. 2020 Feb;8(1):e000350. doi: 10.1136/jitc-2019-000350. J Immunother Cancer. 2020. PMID: 32066647 Free PMC article.
Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer.
Suzuki S, Haratani K, Hayashi H, Chiba Y, Tanizaki J, Kato R, Mitani S, Kawanaka Y, Kurosaki T, Hasegawa Y, Okabe T, Tanaka K, Akashi Y, Ozaki T, Nishio K, Ito A, Nakagawa K. Suzuki S, et al. Among authors: ozaki t. Eur J Cancer. 2022 Jan;161:44-54. doi: 10.1016/j.ejca.2021.11.011. Epub 2021 Dec 15. Eur J Cancer. 2022. PMID: 34922263
Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Okamoto I, Nokihara H, Nomura S, Niho S, Sugawara S, Horinouchi H, Azuma K, Yoneshima Y, Murakami H, Hosomi Y, Atagi S, Ozaki T, Horiike A, Fujita Y, Okamoto H, Ando M, Yamamoto N, Ohe Y, Nakagawa K. Okamoto I, et al. Among authors: ozaki t. JAMA Oncol. 2020 May 1;6(5):e196828. doi: 10.1001/jamaoncol.2019.6828. Epub 2020 May 14. JAMA Oncol. 2020. PMID: 32163097 Free PMC article. Clinical Trial.
Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer.
Hayashi H, Ogura M, Niwa T, Yokoyama T, Tanizaki J, Ozaki T, Yoshioka H, Kurata T, Tamura Y, Fujisaka Y, Tanaka K, Hasegawa Y, Kudo K, Chiba Y, Nakagawa K. Hayashi H, et al. Among authors: ozaki t. Oncologist. 2021 Jan;26(1):19-e52. doi: 10.1002/ONCO.13524. Epub 2020 Sep 28. Oncologist. 2021. PMID: 32918791 Free PMC article. Clinical Trial.
Successful treatment with atezolizumab combination chemotherapy in a patient with high-grade fetal adenocarcinoma of the lung: A case report.
Fujimoto K, Watanabe S, Yasuda Y, Date E, Kawabata Y, Kanemura H, Takahama T, Yonesaka K, Iizuka N, Takahashi KI, Kawakami O, Ozaki T, Nakagawa K. Fujimoto K, et al. Among authors: ozaki t. Thorac Cancer. 2023 Jan;14(2):214-217. doi: 10.1111/1759-7714.14768. Epub 2022 Dec 9. Thorac Cancer. 2023. PMID: 36495048 Free PMC article.
2,053 results